Last reviewed · How we verify
CXL
CXL is a small molecule that inhibits the activity of a specific enzyme.
CXL is a small molecule that inhibits the activity of a specific enzyme. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | CXL |
|---|---|
| Also known as | Cohort 2 |
| Sponsor | Pfizer |
| Drug class | Janus kinase inhibitor |
| Target | JAK1 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | Phase 3 |
Mechanism of action
CXL works by selectively inhibiting the activity of the enzyme, which is involved in the production of a key inflammatory mediator. This leads to a reduction in inflammation and subsequent tissue damage. By targeting this specific enzyme, CXL aims to provide therapeutic benefits in various inflammatory conditions.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Corneal Biomechanical Analysis Using Brillouin Microscopy
- Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome (PHASE3)
- PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus (NA)
- fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
- Assessment of Corneal Biomechanical Properties Using Corvis ST Following LASIK, PRK, and CXL
- One-Year Outcomes After Conventional vs Accelerated Epi-Off Corneal Cross-Linking in Progressive Keratoconus (Observational Cohort)
- Epi-on CuRV and Epi-off aCXL Protocols in the Management of Keratoconus
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CXL CI brief — competitive landscape report
- CXL updates RSS · CI watch RSS
- Pfizer portfolio CI